Genetic Polymorphisms of FcγRIIa and FcγRIIIa Are Not Predictive of Clinical Outcomes after Cetuximab plus Irinotecan Chemotherapy in Patients with Metastatic Colorectal Cancer

Seong Joon Park,Yong-Sang Hong,Jae-Lyun Lee,Min-Hee Ryu,Heung-Moon Chang,Kyu Pyo Kim,Yong-Chel Ahn,Young-Soon Na,Dong-Hoon Jin,Chang Sik Yu,Jin-Cheon Kim,Yoon-Koo Kang,Tae-Won Kim

Genetic Polymorphisms of FcγRIIa and FcγRIIIa Are Not Predictive of Clinical Outcomes after Cetuximab plus Irinotecan Chemotherapy in Patients with Metastatic Colorectal Cancer

2012

Seong Joon Park
Yong-Sang Hong
Jae-Lyun Lee
Min-Hee Ryu
Heung-Moon Chang
Kyu Pyo Kim
Yong-Chel Ahn
Young-Soon Na
Dong-Hoon Jin
Chang Sik Yu
Jin-Cheon Kim
Yoon-Koo Kang
Tae-Won Kim

Objective: The anti-epidermal growth factor receptor monoclonal antibody cetuximab has been shown to be effective in patients with wild-type KRAS metastatic color

Keywords:

Cetuximab
Immunology
KRAS
Epidermal growth factor receptor
Colorectal cancer
Progression-free survival
Biomarker (medicine)
Medicine
Cancer research
Irinotecan
Chemotherapy
Internal medicine
Monoclonal antibody
Growth factor receptor
Oncology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations